Clinical findings present in most SETBP1-HD individuals include: motor developmental delay (97%); developmental delay/mild-to-severe intellectual disability; learning difficulties; speech and language disorder (including childhood apraxia of speech). This evidence concerns the gene SETBP1 and Global developmental delay.